THE CONTEXT
The passage summarizes prevention, delivery, blood pressure control, and magnesium sulfate use, with additional distinctions concerning gestational hypertension and HELLP syndrome.
Prevention and management setting
•
Prevention of eclampsia depends on early detection and management of pre-eclampsia; prophylactic therapy and timely delivery are emphasized.
•
Eclampsia should be managed in a tertiary care hospital.
•
Management includes general care, arresting convulsions, controlling hypertension, and expediting delivery.
•
The passage states that women with eclampsia should be delivered within 6–8 hours even if fits are not controlled.
Diagnostic and management distinctions
•
Gestational hypertension is described as lacking edema, proteinuria, and other hematological changes; blood pressure usually subsides within 12 weeks after delivery.
•
Pre-eclampsia should be differentiated from essential hypertension and chronic renal disease because pregnancy outcomes differ.
•
For severe pre-eclampsia before 34 weeks, delivery depends on criteria referenced in the source but not reproduced in this target passage.
•
Patients with gestational hypertension or atypical pre-eclampsia who meet other diagnostic criteria for severe pre-eclampsia should be treated as having severe pre-eclampsia.
•
HELLP syndrome may develop without maternal severe hypertension and proteinuria.
Blood pressure control and adjunctive treatment
•
This passage gives blood pressure targets of 140–160 mm Hg systolic and 90–105 mm Hg diastolic.
•
Corticosteroids are indicated in cases with preterm delivery and in HELLP syndrome.
Magnesium sulfate indications and duration
•
Magnesium sulfate is indicated in eclampsia, HELLP syndrome, pre-eclampsia with severe features, and unstable mild pre-eclampsia.
•
It is the drug of choice for controlling eclamptic convulsions.
•
Treatment continues for 24 hours after the last seizure or delivery, whichever occurs later.
Repeat dosing and intravenous administration
•
Repeat magnesium sulfate doses require present knee jerks, urine output greater than 30 mL/hour, and a respiratory rate greater than 12/minute.
•
The therapeutic magnesium sulfate level is 4–7 mEq/L.
•
For intravenous administration, magnesium sulfate concentration should not exceed 20%.
•
One part of 50% magnesium sulfate injection is diluted with 1.5 parts of water for injection to produce a 20% solution, which is then administered slowly intravenously.